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Several herbal plants improve medical conditions. Such plants contain many bioactive phytochemicals. Terpenoids (also called
“isoprenoids”) constitute one of the largest families of natural products accounting for more than 40,000 individual compounds
of both primary and secondary metabolisms. In particular, terpenoids are contained in many herbal plants, and several terpenoids
have been shown to be available for pharmaceutical applications, for example, artemisinin and taxol as malaria and cancer
medicines, respectively. Various terpenoids are contained in many plants for not only herbal use but also dietary use. In this
paper, we describe several bioactive terpenoids contained in herbal or dietary plants, which can modulate the activities of ligand-
dependent transcription factors, namely, peroxisome proliferator-activated receptors (PPARs). Because PPARs are dietary lipid
sensors that control energy homeostasis, daily eating of these terpenoids might be useful for the management for obesity-induced
metabolic disorders, such as type 2 diabetes, hyperlipidemia, insulin resistance, and cardiovascular diseases.
1. Diversityof Terpenoids inNature
Nature relies on an intricate network of biosynthetic path-
ways to produce a lot of small organic molecules required to
support life. Terpenoids (also called “isoprenoids”) consti-
tuteoneofthelargestfamiliesofnaturalproductsaccounting
formorethan40,000individualcompoundsofbothprimary
and secondary metabolisms. Most of them are of plant
origin, and hundreds of new structures are reported every
year [1–3]. All organisms naturally produce some terpenoids
aspartofprimarymetabolism,butmanyproduceterpenoids
via secondary metabolism.
Isopentyl diphosphate (IPP) and its isomer dimethy-
lallyl diphosphate (DMAPP) are the universal ﬁve-carbon
precursors of all terpenoids. After the discovery of the
mevalonate (MVA) pathway in yeast and animals, it was
assumed that IPP was synthesized from acetyl-CoA via
MVA and then isomerized to DMAPP in all eukaryotes
and some Gram-positive prokaryotes [2, 3]( Figure 1). The
origins of archeal terpenoids were unknown until recently,
when four of the six enzymes have been identiﬁed to be
present in sequenced genomes [2]. Recently, a nonstandard
MVA pathway involving phosphorylation of isopentenyl
phosphate has been discovered in Methanocaldococcus jan-
naschii [4]. Before 1993, the MVA pathway was the only
known source of terpenoids. After isotope-labeling studies
by Rohmer et al. [5], it has been shown that there is
an alternate pathway to terpenoids that do not originate
from acetyl-CoA. The complete pathway has been ﬁnally
elucidated in 2002 [6]. This alternative MVA-independent
pathway has been named the methylerythritol phosphate
(MEP) pathway (Figure 1), which has been identiﬁed in both
bacteria and plants [2, 3]. Plants use both pathways although
they are compartmentalized: MVA to the cytoplasm and2 PPAR Research
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possibly to mitochondria to provide sterols, the side chain of
ubiquinone, and sesquiterpenes (C15), and MEP to plastids
providing plastidial terpenoids, for example, isoprene (C5),
monoterpenes(C10),diterpenes(C20,includinggibberellins
and the phytyl tail of tocopherols and chlorophylls), and
carotenoids (C40) [3]. Moreover, there is evidence that a
certain degree of crosstalk between the MVA and MEP
pathways can occur, implying that these pathways are not
completely autonomous [7].
Plants have an enormous capacity to synthesize huge
amounts of diverse terpenoids, particularly via the combina-
tion of the terpenoid biosynthetic route and other secondary
metabolic pathways. For instance, tocopherol biosynthesis
occurs as a result of combination of the shikimate and
isoprenoid pathways, which lead to homogentisic acid phytyl
diphosphate, which in combination ultimately lead to the
formation of tocopherols (formed by a chromanol head
group and a phytyl tail) [8].
In addition to universal physiological, metabolic, and
structural functions, many speciﬁc terpenoids function in
various situations, including communication and defense.
Members of the isoprenoid group also include industrially
useful polymers (e.g., rubber and chicle) and agrochemicals
(e.g., pyrethrins and azadirachtin).
It is known that several herbal plants improve medical
conditions. Such plants contain many bioactive phyto-
chemicals. In particular, terpenoids are contained in many
herbal plants, and several terpenoids have been shown to
be available for pharmaceutical applications, for example,
artemisinin and taxol as malaria and cancer medicines,
respectively.Variousterpenoidsarecontainedinmanyplants
for not only herbal medicine use but also dietary use [9].
In this paper, we describe several bioactive terpenoids
(Figure 2) contained in herbal or dietary plants, which
have the potential to ameliorate metabolic disorders via
activationofligand-dependenttranscriptionfactors,namely,
peroxisome proliferator-activated receptors (PPARs).
2. PPARs: Therapeutic Targets of
Metabolic Syndrome
2.1. Nuclear Receptors. Members of the nuclear receptor
superfamily of ligand-dependent transcription factors play
a multitude of essential roles in development, homeosta-
sis, reproduction, and immune functions [10–14]. Ligand
binding induces a conformational change in nuclear recep-
tors, releasing corepressors in exchange for coactivators.
Ligand-activated complexes recruit basal transcriptional
machineries, resulting in an enhanced gene expression.
Nuclear receptors include the classical steroid hormone
receptors (estrogen, progesterone, androgen, glucocorticoid,
and mineralcorticoid receptors); “orphan receptors,” which
exhibit conserved features of the nuclear receptor family but
have not been linked to endogenous ligands; and so-called
“adopted orphan receptors,” which were initially identiﬁed
as orphan receptors but were subsequently linked to endoge-
nous ligands. The adopted orphan receptors include the
thyroid hormone receptors, retinoic acid receptors, PPARs,
and liver X receptors (LXRs). Nearly all members of this
familycontainahighlyconservedDNA-binding domain that
mediates sequence-speciﬁc recognition of target genes and
a C-terminal domain that determines the speciﬁc ligand-
binding properties of each receptor and mediates ligand-
regulated transcriptional activation and/or repression [10].4 PPAR Research
Nuclear receptors are frequent biological targets of active
compounds contained in herbal and dietary plants. This is
perhaps not surprising, since nuclear receptors evolved to
be regulated by lipophilic molecules derived from diet and
the environment [15, 16]. At least ten of these receptors have
been shown to be directly activated by compounds puriﬁed
fromherbalremedies[16].Somecompoundshaveacomplex
pharmacology; for example, grapeseed-derived resveratrol is
al i g a n do fe s t r o g e nr e c e p t o r sa n dP P A R s[ 17, 18] but has
also been suggested to activate sirtuin 1 (SIRT1), an NAD+-
dependent protein deacetylase enzyme implicated in the
biology of aging [19]. Other phytochemicals target multiple
nuclear receptors [16].
2.2. PPARs. PPARs are members of the nuclear receptor
superfamily, which are activated by fatty acids and their
derivatives. PPARs are dietary lipid sensors that regulate
lipid and carbohydrate metabolism [20]. In mammals, three
subtypes of PPAR, α, δ,a n dγ,w e r ef o u n d[ 21]. PPARs
form heterodimers with retinoid-X-receptors (RXRs) and
bind to consensus DNA sites composed of direct repeats
(DRs) of hexameric DNA sequences (AGGNCA) separated
by 1bp (DR1). In the absence of ligands, PPAR-RXR
heterodimers recruit corepressors and associated histone
deacetylases and chromatin-modifying enzymes, silencing
transcription by so-called active repression [22–24]. Ligand-
binding induces a conformational change in PPAR-RXR
complexes, releasing repressors in exchange for coactivators.
Ligand-activated complexes recruit the basal transcriptional
machinery, resulting in an enhanced gene expression.
PPARα is highly expressed in the liver, cardiac muscle,
anddigestivetract,andregulatetheexpressionoftargetgenes
involved in lipid catabolism. Activators of PPARα,s u c ha s
ﬁbrates, decrease circulating lipid levels and are commonly
used to treat hypertriglyceridemia and other dyslipidemic
states [25]. PPARδ is expressed in many tissues including
the skeletal muscle and brown adipose tissue. Recently,
it has been suggested that PPARδ activation attenuates
obesity and type-2 diabetes [26, 27]. PPARγ is abundant
in adipose tissues functioning as the key transcription
factor for adipogenesis. Synthetic ligands for PPARγ,s u c h
as thiazolidinediones, are increasingly used to treat type-2
diabetes [28].
PPARs are involved in not only energy homeostasis but
alsoinﬂammation.PPARαregulatesinﬂammatoryprocesses,
mainlybyinhibitinginﬂammatorygeneexpression.Inrecent
years, several molecular mechanisms responsible for the
immunosuppressive eﬀects of PPARα have been uncovered
[29]. These include interference with several proinﬂamma-
tory transcription factors [30]. The number of studies that
have addressed the role of PPARδ during inﬂammation
is limited. So far, an anti-inﬂammatory eﬀect has been
observed in macrophages suggesting a possible role for
PPARδ in the process of atherogenic inﬂammation. [31].
Similar to PPARα,P P A R γ is involved in governing inﬂam-
matory response, particularly in macrophages. Currently,
two diﬀerent molecular mechanisms have been proposed by
which anti-inﬂammatory actions of PPARγ are eﬀectuated:
(1) via interference with proinﬂammatory transcription
factors [32] and (2) by preventing removal of correpressor
complexes from gene promoter regions resulting in suppres-
sion of inﬂammatory gene transcription [33].
Recently, it has been indicated that obesity is associated
with a low-grade chronic inﬂammation state [34]. The
inﬂammatory condition in obesity is increasingly being
recognized as an important contributor to the development
of metabolic syndrome and its associated complications.
Adipocytes can secret cytokines involved in inﬂammation,
such as adiponectin, monocyte chemoattractant protein-1
(MCP-1), and tumor necrosis factor-α (TNF-α)[ 35]. MCP-
1, a member of the CC chemokine superfamily, plays a piv-
otal role in monocyte/macrophage traﬃcking and activation
[36]. Macrophages also produce various proinﬂammatory
factors including MCP-1 and TNF-α. Macrophage-derived
TNF-α establishes a vicious cycle that augments inﬂamma-
tory changes and insulin resistance in obese adipose tissues
[37]. Therefore, to prevent obesity-related inﬂammation, it
is important to decrease the production of obese-adipose-
tissue-derived proinﬂammatory factors such as MCP-1 and
TNF-α.
Several herbal and dietary plants improve medical con-
ditions including diabetes mellitus, hyperlipidemia, and car-
diovascular disease associated with an abnormality of lipid
metabolism [38, 39]. To screen for novel natural ligands for
PPARs, we have evaluated PPAR ligand activities for various
terpenoids in an advanced highly sensitive system with
the coexpression of a coactivator for nuclear receptors, the
cAMP-response element-binding protein (CREB)-binding
protein (CBP), developed by modifying the luciferase
reporter assay system [40]. Hereinafter, we describe several
terpenoids, identiﬁed as novel PPAR ligands, in our PPAR
ligand screening.
3. Novel Functions of DietaryTerpenoids
asPPAR Ligands
3.1. Isoprenols. We carried out screening for novel PPAR
ligandsinnaturalcompoundscontained inmedicinal plants.
We used several terpenoids including carotenoids and poly-
isoprenoid alcohols (isoprenols) for the screening, because
these compounds are contained in many medicinal and
dietary plants [41]. These terpenoids have multifunctions
such as the suppression of tumor proliferation [41–43],
apoptosis-inducing activity [9], and cation channel regu-
lation [44]. Some terpenoids, which are intermediates in
cholesterol synthesis, regulate the activity of 3-hydroxy-3-
methylglutaryl-coemzyme A (HMG-CoA) reductase, a key
enzyme in cholesterol synthesis by controlling the degra-
dation of the enzyme [45, 46]. Such functions of dietary
terpenoids are signiﬁcant for the trials to manage disease
conditions such as cancers or cardiovascular diseases using
food factors.
AsshowninFigure 3,severalterpenoidsactivatedPPARγ
at a concentration of 50 or 100μM[ 40]. In this assay, we
identiﬁed that isoprenols, such as geraniol, farnesol, and
geranylgeraniol (chemical structures are shown in Figure 2)
have a potential to activate PPARγ as novel ligands. AtPPAR Research 5
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Figure 3: Eﬀects of various terpenoids on the activation of PPARγ ligand and chemical structures of active terpenoids. PPARγ activity
in monkey CV-1 kidney cells was determined by luciferase reporter assay using advanced highly sensitive GAL4/PPARγ chimera system
d e s c r i b e di n[ 40]. After 24 hours of incubation with or without each terpenoid at 50 or 100μM, luciferase activity was measured. The
activity of a vehicle control was set at 100% and the relative luciferase activities are presented as fold induction compared with that of the
vehicle control. The values are means ± S.E.M. of 3-4 replicates. B: Chemical structures of active terpenoids.
100μM, the activations by geraniol, farnesol, and geranyl-
geraniol were 2.2-, 4.1-, and 3.7-fold that by the vehicle
control, respectively. On the other hand, squalene had no
eﬀect on PPARγ transactivation. Although geraniol had no
eﬀect on PPARα, farnesol and geranylgeraniol also dose-
dependently activated PPARα (10- and 8.6-fold increases at
a concentration of 100μM compared with vehicle controls,
respectively) in the PPARα ligand assay system [40]. These
activities were so potent and nearly the same as that of 10μM
fenoﬁbrates, one of the ﬁbrates (antihyperlipidemia drugs)
used as a positive control for PPARα. In this regard, these
farnesol and geranylgeraniol isoprenols have the eﬀects of
dual activation of PPARγ and PPARα.
PPARγ activation in adipose tissues results in the
improvement of insulin resistance [46]a n dP P A R α acti-
vation in the liver induces the lowering of circulating
lipid levels [47]. These eﬀects are due to the regulation
at mRNA expression levels of target genes of PPARs.
The addition of each isoprenol induced mRNA expression
of PPAR target genes in 3T3-L1 adipocytes and HepG2
hepatocytes [40]. Therefore, it is possible that isoprenols
could regulate insulin resistance and/or circulating lipid
levels. The ﬁnding of the dual activation of PPARγ and
PPARα by isoprenols is very important for thinking of
the mechanisms understanding the eﬀects of medicinal
plants and valuable for the management of diabetic and
hyperlipidemicconditionsinherbalmedicine.Indeed,inour
preliminary study, farnesol ameliorated hyperglycemia in
high fat diet-fed wild-type mice but not in PPARα deﬁcient
mice (Goto et al., unpublished data). These ﬁndings indicate
that improvement of obesity-associated metabolic disorders
by farnesol is mainly dependent on PPARα activation. These
results provide not only a signiﬁcant molecular basis on how
herbal plants containing phytochemicals such as isoprenols
induce the improvement of diabetes or hyperlipidemia, but
also possibilities that phytochemicals might have therapeutic
applications in lipid abnormalities, such as obesity, diabetes
mellitus, and hyperlipidemia.
3.2. Phytol. Phytol, a diterpene alcohol, which is a carbon
side chain of a chlorophyll molecule (Figure 2), is involved
in the production of energy from light. Phytol is a plastidial
terpenoid and synthesized via the MEP pathway in plastids
[48]. Since almost all photosynthetic organisms use chloro-
phylls, phytol is also abundantly present in nature including
various vegetables. It is suggested that chlorophyll molecules
are partially digested and the phytol moiety is released in
animals [49]. Then, the released phytol is absorbed in the
small intestine and converted to phytanic acid in the liver.
Phytanic acid is a branched-chain, terpenoid-derived
fatty acid constituent of diet (Figure 2). In surveys of
phytanic acid content of a variety of food products, high
levels were indeed found in products such as milk, butter,
cheese, meat from cows, sheep, and some ﬁsh and ﬁsh oils,
whereas no phytanic acid is present in vegetables [50]. This
compound can also be produced from the conversion of
dietary phytol in the body [51]. Phytanic acid has been
reported to activate PPARγ and the retinoid-X-receptor
(RXR) [52, 53] so that diﬀerentiation is stimulated in both
white and brown adipocytes [52]. In addition, phytanic acid
stimulates PPARα to regulate lipid metabolism in some types6 PPAR Research
of cell [54]. Therefore, the intake of phytol as a precursor
of phytanic acid may be valuable for the management of
lipid metabolism through the activation of PPARs. Indeed,
a phytol-enriched diet increased plasma and hepatic levels of
phytanic acid, and induced the mRNA expression of PPARα
target genes involved in peroxisomal and mitochondrial β-
oxidation and fatty acid metabolism [55].
However, since the conversion of phytol into phytanic
acid is not very rapid, a phytol-enriched diet also induced
accumulation of phytol in the liver [56]. Moreover, as
described previously, several terpenoids, which resemble
phytol in structures, activate PPARs in adipocytes and
hepatocytes [40]. In this sense, it must be valuable to analyze
the eﬀects of phytol itself as an activator of PPARs.
Therefore, we evaluated the eﬀects of phytol on PPAR
activity using our advanced highly sensitive luciferase assays
(Figure 3). Among the PPAR isoforms, PPARα was activated
the most markedly following the addition of phytol [57].
The eﬀects of phytol on PPARα activation were larger than
those of phytanic acid under our experimental conditions.
Phytol induced the mRNA and protein expression of PPAR
target genes in a manner dependent on the level of PPARα
expression in HepG2 hepatocytes. In our in vitro coactivator
recruiting assay, it was revealed that phytol can activate
PPARαdirectly[57].Theseﬁndingsindicatethatphytolitself
can directly bind to PPARα as its ligand.
Because the activation of PPARα is one of the most
important factors in lipid metabolism in peripheral tissues
including the liver and muscles, the ability of phytanic
acid and phytol to activate PPARα is very important in
the management of lipid metabolism using food factors.
Induction of PPARα target gene expression in mice fed a
phytol-enriched diet [55] is likely due to not only phytanic
acid but also phytol. It is considered that such eﬀects of
phytol are valuable for the control of lipid abnormalities in
common diseases including obesity, diabetes, and hyperlipi-
demia through PPARα activation in the liver.
3.3. Abietic Acid Derivatives. The amount of variety of
hydrocarbons and their derivatives used in industrial and
commercial activities has been increasing over the years.
Abieticacidisatricyclic-diterpenecarboxylicacid(Figure 2),
and is the main component of the rosin fraction of oleoresin
synthesized by conifer species, such as grand ﬁr (Abies gran-
dis) and lodgepole pine (Pinus contorta)[ 58]. Abietic acid is
commonly used as a ﬂuxing agent in solder, as a paper sizing
agent to make paper more water resistant, and in printing
inks, adhesives, and plasticizers [59]. Moreover, it has been
reported that abietic acid is a bioactive compound and it has
an anti-inﬂammatory eﬀect. In lipopolysaccharide (LPS)-
stimulated macrophages, abietic acid suppresses production
of prostaglandin E2 (PGE2) in vitro and in vivo [60].
To investigate whether the activation of PPARs is related
to the anti-inﬂammatory eﬀects of abietic acid and its
derivatives, we evaluated the eﬀects of abietic acid and its
derivatives on PPAR activity (Figure 2). Abietic acid and
dehydroabietic acid, one of major components of colophony
(also known as Rosin and pine resin), potently activated
both PPARα and PPARγ but not PPARδ [61, 62]. Similarly
to thiazolidinedione, a synthetic PPARγ ligand, abietic acid
suppressed mRNA expressions of TNF-α and cyclooxygenase
2 (COX2), which are induced in inﬂammatory reactions,
in LPS-stimulated macrophages [61]. Dehydroabietic acid
stimulated PPARα and PPARγ more potently than abietic
acid [62]. Dehydroabietic acid signiﬁcantly suppressed the
production of proinﬂammatory mediators such as MCP-
1, TNF-α, and NO in LPS-stimulated macrophages and in
the coculture of macrophages and adipocytes [62]. In obese
diabetic KK-Ay mice, dietary dehydroabietic acid suppressed
obesity-associated elevation of circular MCP-1 and TNF-α
levels and their mRNA expressions in white adipose tissues.
Moreover, dehydroabietic acid improved carbohydrate and
lipid metabolism [63]. These ﬁndings indicate that the
anti-inﬂammatory eﬀects of abietic acid and dehydroabietic
acid are at least partly due to the activation of PPARs.
Additionally, it is suggested that these compounds can be
used not only for anti-inﬂammation but also for regulating
carbohydrate and lipid metabolism and atherosclerosis.
3.4. Auraptene. Citrus-fruit-derived compounds have many
beneﬁcial bioactivities (e.g., anticarcinogenic, antihyper-
tension, and anticardiovascular disease eﬀects) [64, 65].
Through our screening for PPARs ligands (Figure 2), we
identiﬁed auraptene, a geraniol coumarin ether, as a novel
PPARα and PPARγ ligand [66, 67]. Auraptene (Figure 2)
occurs in a variety of citrus fruits. It has been reported
that auraptene has anti-inﬂammatory and anticarcinogenic
activities. In cultured adipocytes, auraptene upregulated
an antiatherosclerotic, antidiabetic, and anti-inﬂammatory
cytokine, adiponectin, and downregulated a proinﬂamma-
tory cytokine, MCP-1. These eﬀects disappeared in the
presence of GW9662, a PPARγ antagonist [66], suggesting
that auraptene improves adipocytokine proﬁles via the
activation of PPARγ. In addition, mRNA expressions of
several PPARα target genes involved in FA catabolism, were
also induced in PPARα-expressing HepG2 hepatocytes by
auraptene treatment [67]. It is likely that auraptene regulates
the mRNA expressions of both PPARγ and PPARα target
genes as a dual agonist, and these activities might contribute
to the anti-cardiovascular disease eﬀect of citrus fruits.
3.5. Bixins. Annatto obtained from the pericarp of seeds
from Bixa orellana is a natural pigment extensively used
in many processed foods [68, 69]. Bixin and norbixin
(Figure 2), which are carotenoids, are the main components
of this pigment, and have been reported to possess antiox-
idative and anticarcinogenic eﬀects [70–72]. Furthermore,
it has also been indicated that both annatto extract and
norbixin have hypoglycemic eﬀects in nonobese dogs and
mice, respectively [73, 74]. In PPARγ ligand assay, both
bixin and norbixin activated PPARγ (Figure 2), and bixin
induced PPARγ target genes in 3T3-L1 adipocytes, resulting
in the promotion of adipocyte diﬀerentiation and insulin-
stimulated glucose uptake [75]. Therefore, the hypoglycemic
eﬀects of annatto and norbixin might be caused by the
activation of PPARγ.PPAR Research 7
4. Conclusions
Inthispaper,wementionedthediversityofterpenoids,func-
tionsofPPARs,andseveralterpenoidsactivatingPPARs.The
prevalence of obesity worldwide has progressively increased
over the past decades. This unabated rise has spawned
proportionate increases in obesity-associated metabolic dis-
orders. Currently, synthetic PPAR agonists are widely used
for the treatment of metabolic disorders. Daily intake of
dietary terpenoids, which activate PPARs as we described
above, may be valuable for the control of carbohydrate and
lipid disorders. Dietary patterns rich in vegetables and fruit
areassociatedwithalowerprevalenceofmetabolicsyndrome
[65, 76]. Because most of the terpenoids are of plant origin
and they are contained in vegetables and fruit, dietary
terpenoids may contribute to a decrease in risk of metabolic
syndrome. Moreover, because the terpenoids constitute one
of the largest families of natural products, more potent and
useful PPAR activators may exist.
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